ArticleClinical and experimental medicine2026
The association between non-alcoholic fatty liver disease with blood selenium level based on the NHANES 2017-2020.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The present study aims to investigate the relationship between blood selenium and NAFLD. Data were obtained from the National Health and Nutrition Examination Survey (2017-2020), a total of 3940 eligible participants were included in this study. Multivariable logistic regression, subgroup analyses, and smooth curve fitting assessed the blood selenium-NAFLD relationship. A piecewise linear regression model identified potential thresholds. Model robustness was evaluated using multiple imputation. Among 3,940 participants, NAFLD prevalence was 45% (n = 1,173). Compared to the lowest blood selenium quartile (Q1: 103.10-169.49 µg/L), the adjusted odds ratios for NAFLD were 1.44 (95% CI: 1.16-1.78; P < 0.01) in Q3 (184.56-201.29 µg/L) and 1.26 (95% CI: 1.02-1.57; P = 0.035) in Q4 (201.30-562.23 µg/L) after full covariate adjustment (Q2 was non-significant). Each 1-standard deviation increase in log-transformed blood selenium corresponded to an adjusted odds ratios of 1.16 (95% CI: 1.08-1.26) for NAFLD. Gender significantly modified this association (P for interaction < 0.05). Adjusted smooth curve fitting demonstrated a significant non-linear positive dose-response relationship (P for non-linearity = 0.026). Elevated blood selenium concentration is significantly associated with an increased risk of NAFLD in US adults, exhibiting a non-linear dose-response pattern. This finding requires confirmation in future prospective cohort studies. Such association, if confirmed, will be of considerable public health relevance given the epidemic of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.